For now, unfortunately, we're going to leave that up to your imagination.

This is a new paradigm in information in an emerging market.

Our Board and management team are united in the belief that we must take bold action now to lead the emerging era of molecular medicine with leading positions in both genetic and protein analysis.

We're having a great time right now, we're enjoying this, as you might imagine. It's easy to get caught up in the euphoria when everything is going well.